These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35031785)

  • 21. Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer.
    Gritsina G; Gao WQ; Yu J
    Asian J Androl; 2019; 21(3):215-223. PubMed ID: 30950412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
    Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
    Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
    Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic modulations and lineage plasticity in advanced prostate cancer.
    Ge R; Wang Z; Montironi R; Jiang Z; Cheng M; Santoni M; Huang K; Massari F; Lu X; Cimadamore A; Lopez-Beltran A; Cheng L
    Ann Oncol; 2020 Apr; 31(4):470-479. PubMed ID: 32139297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
    Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Xiao GQ; Ho G; Suen C; Hurth KM
    Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging of Neuroendocrine Prostatic Carcinoma.
    Taher A; Jensen CT; Yedururi S; Surasi DS; Faria SC; Bathala TK; Mujtaba B; Bhosale P; Wagner-Bartak N; Morani AC
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.
    Choe H; Sboner A; Beltran H; Nanus D; Tagawa ST
    Thromb Res; 2016 Apr; 140 Suppl 1():S192. PubMed ID: 27161731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer.
    Macciò A; Gramignano G; Madeddu C
    J Pain Symptom Manage; 2015 Aug; 50(2):e1-4. PubMed ID: 26004402
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical features of neuroendocrine prostate cancer.
    Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
    Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metastatic castration-resistant prostate cancer].
    Henriques V; Wenzel M; Demes MC; Köllermann J
    Pathologe; 2021 Jul; 42(4):431-441. PubMed ID: 34170384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
    Beltran H; Jendrisak A; Landers M; Mosquera JM; Kossai M; Louw J; Krupa R; Graf RP; Schreiber NA; Nanus DM; Tagawa ST; Marrinucci D; Dittamore R; Scher HI
    Clin Cancer Res; 2016 Mar; 22(6):1510-9. PubMed ID: 26671992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer.
    Long Z; Deng L; Li C; He Q; He Y; Hu X; Cai Y; Gan Y
    Cell Death Dis; 2021 Jan; 12(1):46. PubMed ID: 33414441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.
    Hu CY; Wu KY; Lin TY; Chen CC
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
    Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
    Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.
    Kesch C; Yirga L; Dendl K; Handke A; Darr C; Krafft U; Radtke JP; Tschirdewahn S; Szarvas T; Fazli L; Gleave M; Giesel FL; Haberkorn U; Hadaschik B
    Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):385-389. PubMed ID: 34226953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.